Logo on white.png
EsoCap reports positive topline results from ACESO Phase II trial investigating ESO-101 in eosinophilic esophagitis
December 05, 2023 03:00 ET | EsoCap AG
ESO-101, EsoCap's lead product candidate, consists of a capsule with a rolled-up, thin mucoadhesive film with the anti-inflammatory corticosteroid, mometasone furoateEsoCap's novel targeted delivery...
Logo on white.png
EsoCap completes patient recruitment in ACESO Phase II trial in eosinophilic esophagitis
September 05, 2023 03:30 ET | EsoCap AG
EsoCap's novel targeted delivery platform is designed to increase mucosal contact time and drug deposition in the esophagus ESO-101, EsoCap's lead product candidate, consists of a capsule with a...
Logo on white.png
EsoCap holds a multidisciplinary advisory board meeting on Barrett’s esophagus
June 14, 2022 03:32 ET | EsoCap AG
EsoCap AG organized a multidisciplinary scientific advisory board meeting with eight international experts in Barrett’s esophagus (BE) in ZurichEsoCap’s technology for the topical treatment of...
Logo on white.png
EsoCap supports first European EoE Day of the European Society of Eosinophilic Oesophagitis on May 22, 2022
May 20, 2022 05:00 ET | EsoCap AG
Patients with eosinophilic esophagitis (EoE) suffer from severe symptoms including swallowing disorders, food impaction, vomiting, and heartburnEsoCap is currently conducting a randomized,...
Logo on white.png
EsoCap and Upadia sign exclusive licensing agreement combining EsoCap technology with Upadia antibodies for the treatment of Barrett’s esophagus
January 10, 2022 05:32 ET | EsoCap AG
Licensing deal grants EsoCap exclusive access to Upadia’s monoclonal antibodies for a local therapy for Barrett’s esophagusBarrett’s esophagus, a disease of the esophagus with high unmet medical need,...
Logo on white.png
EsoCap secures new funding
November 18, 2021 08:30 ET | EsoCap AG
EsoCap successfully closes a private financing round, with investments from existing and new investorsThe new funding was facilitated by EsoCap benefitting from a unique programme implemented by the...
Logo on white.png
EsoCap announces first patient enrolled in Phase II eosinophilic esophagitis trial
October 26, 2021 03:00 ET | EsoCap AG
Randomized, placebo-controlled, double-blind Phase II trial to treat 42 patients ongoing in four European countries with ESO-101ESO-101, EsoCap’s lead product candidate, consists of a capsule with a...
Diagram of EsoCap application, Krause et al. 2020. © EsoCap AG
EsoCap – unique targeted application platform to treat the upper gastrointestinal tract
September 09, 2021 03:00 ET | EsoCap AG
EsoCap’s targeted application technology drastically increases mucosal contact time and enables effective local treatment of various esophageal diseases for the first timeProof of principle in human...